SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $2,048,808,191 |
| Positions | 104 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | COM | $206,983,729 | 1,105,210 |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $123,792,910 | 2,179,069 |
| ELI LILLY & CO | LLY | COM | $118,383,741 | 98,700 |
| MADRIGAL PHARMACEUTICALS INC | MDGL | COM | $93,965,713 | 174,999 |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $93,438,835 | 798,145 |
| RHYTHM PHARMACEUTICALS INC | RYTM | COM | $76,899,156 | 692,598 |
| KYMERA THERAPEUTICS INC | KYMR | COM | $51,963,399 | 453,156 |
| ARGENX SE | ARGX | SPONSORED ADR | $48,939,868 | 52,750 |
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $45,009,000 | 168,750 |
| XENON PHARMACEUTICALS INC | XENE | COM | $41,280,627 | 683,907 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.